Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
The announcement came during the inauguration of the college’s Innovation & Incubation Centre and Health Club
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Ryght AI tackles these hurdles with its AI Site Twin platform
Clinical trial enrollment has long been a bottleneck in drug development
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
Subscribe To Our Newsletter & Stay Updated
